ARTICLE | Company News
G-BA says additional benefit for Bosulif 'unquantifiable'
October 18, 2013 12:23 AM UTC
Germany's Federal Joint Committee (G-BA) said Orphan drug Bosulif bosutinib from Pfizer Inc. (NYSE:PFE) has an "unquantifiable" additional benefit for adults with chronic, accelerated or blast phase P...